The rapid growth of the UC Davis Health System has spurred plans for a new eye center to accommodate the expanding needs of patients and the university.
Science Market Update
If you watch the evening news in Northern California, it's not unusual to hear the results of studies being done at Sacramento's UC Davis Medical Center campus, especially if those results are raising eyebrows. But an autism study out of the M.I.N.D. Institute at UCDMC has gone national recently, appearing on dozens of media outlets, as well as in Monday's issue of the journal Pediatrics. The news? Research study results showing a corellation between a mother's obesity during pregnancy and increased risk for autism in her child. More specifically, women with metabolic diseases like obesity, diabetes, and hypertension were 1.6 times more likely to have children with autism spectrum disorders than healthy women.
The UC Davis Cancer Center was recently recognized as a "comprehensive" center by the National Cancer Institute (NCI). This is the most prestigious honor that a cancer center can receive and designates the renamed, UC Davis Comprehensive Cancer Center as one of the top cancer research institutions in the country.
Tags: biomedical sciences, University of California Davis, cancer research, Southwest, California, UC Davis Cancer Center, BioResearch Product Faire Event, BRPF, Biomedical Research Funding, Cancer Center, Sacramento Campus
On January 25th of this year we held our 9th semiannual Sacramento BioResearch Product Faire event on the medical campus of the University of California Davis, in Sacramento. The UC Davis Health System includes the School of Medicine, School of Nursing, and the Medical Center with its state-of-the-art teaching hospital. Also part of the Sacramento biomedical hub where we hold our events are the UC Davis Children's Hospital and the Shriner's Hospital for Children of Northern California.
The NIH recently awarded more than $110M in research funding for the second phase of the Knockout Mouse Project (KOMP), a phenotyping project involving an international consortium of researchers (the IKMC) who will generate about 5,000 strains of knockout mice that will undergo a large battery of clinical phenotype tests to reveal how traits are affected by deleting a given gene in an individual mouse.
Fragile X Syndrome is the leading cause of inherited mental illness, ranging from learning disabilities to more severe cognitive or intellectual disabilities, including autism. Connecticut pharmaceutical company Marinus, Inc. has developed the synthetic neurosteroid Ganaxolone for the treatment of Fragile X Syndrome (FXS), epilepsy, and Post-Traumatic Stress Disorder (PTSD). Now researchers at UC Davis have been awarded a $3 Million molecular biology research grant by the Department of Defense to study the effects of the drug on FXS specifically.
The UC Davis Department of Biomedical Engineering was founded in 2001 with three faculty members. It now has a faculty of 27 (with 5 more planned) and ranks impressively in the latest NSF Report on R&D Expenditures by major institutions. According to Dept. Chair Athanasiou, UCD BME ranks: